摘要
背景:T细胞急性淋巴细胞白血病(T-ALL)是一种骨髓和淋巴母细胞疾病,主要表现在T细胞免疫表型上。 TALL 患者的诊断显示外周血管中的大肿瘤和白血病细胞的负担经常渗入中枢神经系统。 目的:化疗被认为是该疾病的主要治疗方式,但最近对该疾病分子理解的进展,包括 NOTCH1 信号传导,可以提供一些替代方案。在大多数 T-ALL 中,NOTCH 信号在 NOTCH1 处发生非调节突变。 γ-分泌酶 (GS) 在阻断 NOTCH 受体的蛋白水解激活中起关键作用,这可能成为治疗此类白血病的新靶向疗法。本研究主要旨在概述 γ-分泌酶抑制剂通过 NOTCH 信号传导在 TALL 中的作用。 结果:GSI(γ-分泌酶抑制剂)在大多数 T-ALL 细胞系中的作用与 NOTCH 信号的靶向通路有关。然而,由于多种因素,包括 NOTCH 通路活性的基因表达,NOTCH1 的突变不能作为 γ-分泌酶抑制剂敏感性的预测因子。因此,尽管这种方法在 NOTCH-1 激活的 T-ALL 中取得了有希望的结果,但并非所有患有这种疾病的患者都会有反应。 结论:单一疗法很少能取得针对癌细胞的长期治疗成功,甚至针对研究性通路(如 NOTCH)也可能需要联合方案。最终,这些新治疗药物的优化使用可能成为我们寻找有效“个体化药物”的下一个工具。
关键词: γ-分泌酶抑制剂、T-ALL、NOTCH1、突变、癌症、靶向治疗。
图形摘要
Current Drug Targets
Title:Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia
Volume: 22 Issue: 15
关键词: γ-分泌酶抑制剂、T-ALL、NOTCH1、突变、癌症、靶向治疗。
摘要:
Background: T-cell acute lymphoblastic leukemia (T-ALL) is a diseased condition of bone marrow and lymphoblast, mainly expressed on T-cell immune phenotype. Diagnosis of TALL patients shows the burden of a large tumour and leukemia cells in the peripheral blood vessel which often infiltrates into the central nervous system.
Objective: Chemotherapy is considered the primary mode of treatment for this disease, but recent advancements in the molecular understanding of the disease, including NOTCH1 signaling, could offer some alternatives. NOTCH signaling undergoes a non-regulated mutation at NOTCH1 in most T-ALL. Gamma-secretase (GS) plays a key role in blocking of proteolytic activation of NOTCH receptors, which could potentially be a new targeted therapy for this type of leukaemia. This study mainly aims to outline the role of γ-secretase inhibitors via NOTCH signaling in TALL.
Results: The role of GSI (γ-secretase inhibitor) in most T-ALL cell lines has been linked to the targeting pathway of NOTCH signaling. Mutation at NOTCH1 has however not served as a predictor of γ-secretase inhibitor sensitivity because of several factors, including gene expression of NOTCH pathway activity. Therefore, despite the promising outcome of this approach in NOTCH-1 activated T-ALL, not all patients with this condition are expected to respond.
Conclusion: Long-term therapeutic success against cancerous cells is rarely achieved with monotherapy, and even targeting investigational pathways such as NOTCH may require a combination regimen. Ultimately, the optimised use of these new therapeutic agents may become the next tool in our search for an effective ‘individualized medicine’.
Export Options
About this article
Cite this article as:
Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia, Current Drug Targets 2021; 22 (15) . https://dx.doi.org/10.2174/1389450122666210203192752
DOI https://dx.doi.org/10.2174/1389450122666210203192752 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synergistic Activities of a Silver(I) Glutamic Acid Complex and Reactive Oxygen Species (ROS): A Novel Antimicrobial and Chemotherapeutic Agent
Current Medicinal Chemistry Alterations of Sex Differentiation in Males: From Candidate Genes to Diagnosis and Treatments
Current Pharmaceutical Design On the Search for Skin Gene Therapy Strategies of Xeroderma Pigmentosum Disease
Current Gene Therapy Sentinel Lymph Node Mapping in Early Stage Endometrial Cancer Patients in Low-Resource Settings
Current Women`s Health Reviews Renal Cell Cancer and Positron Emission Tomography- an Evolving Diagnostic and Therapeutic Relationship
Current Medical Imaging Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
Current Medicinal Chemistry New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier
Current Pharmaceutical Design Vascular Resection in Pancreaticoduodenectomy: Is it Worthwhile?
Current Drug Targets 1,5-Diaryl-3-oxo-1,4-pentadienes: A Case for Antineoplastics with Multiple Targets
Current Medicinal Chemistry Hypoxia Helps Glioma to Fight Therapy
Current Cancer Drug Targets Transient Receptor Potential Channels, the Kidney and Hypertension
Current Hypertension Reviews Angiogenesis and AngiomiRs in Non-Hodgkin´s Lymphomas
Current Angiogenesis (Discontinued)